Amit Dutt, Ph.D.

Principal Investigator, Scientific Officer G, ACTREC, Navi Mumbai, adutt@actrec.gov.in
https://www.actrec.gov.in/pi-webpages/AmitDutt/dutt_index.html and https://actrec.gov.in/dr-amit-dutt

ACADEMIC QUALIFICATION

Ph.D in Developmental Biology, University of Zürich, Switzerland	2000-2004
Ph.D in Chloroplast Biology, ICGEB (Int Center for Genetic Engg & Biotech) / Jamia Millia Islamia	1998-2000

PROFESSIONAL EXPERIENCE/ EMPLOYMENT

Principal Investigator, Scientific Officer "G", ACTREC, Tata Memorial Center, Navi Mumbai	2010- till date
Post Doctoral Research Fellow, Broad Institute of MIT & Harvard (Cancer Genomics)	2005-2010
Post Doctoral Research Fellow, Univ Hosp of Zurich, Switzerland (Prion Biology)	2004-2005

HONORS & AWARDS

- Tata Innovation Fellowship Award, Depart of Biotechnology, Govt of India
- Featured among top 75 scientists of India, across all disciplines, shaping the future of the country by DST- 2022
- YIM Boston Young Scientist Award 2018
- Distinguished Alumni Award, conferred by the Vice Chancellor, Jamia Millia Islamia,
- Shanti Swarup Bhatnagar Prize for Science and Technology 2017 in Medical Sciences
- Wellcome Trust/ DBT India Alliance Intermediate Fellowship
- Ramalingaswami Fellowship Award, Department of Biotechnology, Govt of India
- Swiss National Science Foundation Postdoctoral fellowship Award, Switzerland
- Julius Klaus Foundation Fellowship Award, University of Zürich, Switzerland.

PATENTS

Title: Novel fusion transcripts, composition and use thereof in treating cancer
Applicant: ACTREC- Tata Memorial Centre
Inventors: **Amit Dutt**, Bhasker Dharavath, Pawan Upadhyay, and Sudhir Nair
Patent Application: 202321054451 **Ref. No.:** E- 8000 1/63425/2023-MUM; **C.B.R. No.:** 32046

HONORARY MEMBERSHIPS

Government Organizations

- Core Selection and Review Committee for Shanti Swarup Bhatnagar Prize.
- Review Committee Member for Haryana Vigyan Ratna Award and Haryana Yuva Vigyan Ratna Award.
- **CSIR** Expert Monitoring Committee: Pan CSIR Cancer Research Program & Indian Breast Cancer Genome Atlas
- **Department of Biotechnology** Core Expert Committee Member: DBT- Unique Methods of Management of Inherited Disease (UMMID), DBT HGG-Innovative Young Biotechnologist Award (IYBA), DBT-Indo Australian Biotechnology Fund, DBT-Ramalingawamy Fellowship Scheme (RLS), DBT- Med Biotech-I, DBT-Human Genetics & Genome Analysis (HGG), DBT- Establish of Bioinfo and Comp Biol in India, & Cancer Disease Biology (CDB).
- **Department of Science and Technology** Core Expert Committee Member for:Science and Engineering Research Board, Govt of India: SERB Empowerment and Equity Opportunities for Excellence in Science (EMEQ), DST SERB Early Career Research Award (ECRA), Start-up Research Grant (SRG), National Post Doctoral Fellow (NPDF), Core Research Grant (CRG), SIRE, and SUPRA.
- **ICMR** Core Member: Precision Oncology Taskforce; PSC Dev Res- Artificial Intelligence (Oncology & CVD)
- Expert DBT-NCI/ AIIMS India Translational & Clinical Research Partnership Center for Cancer Genomics
- Scientific Reviewer, TTCRC, TMC, Kolkata
- Scientific Advisory Committee, 4baseCare- an Onco-Tech company, Bangalore
- Scientific Advisory Committee and SRC Member, Institute of Advanced Virology (IAV), Kerala Biotech Commission.
- Scientific Advisory Committee, Member, Institute of Bioinformatics and Biotechnology, Bangalore
- Scientific Advisory Committee, Member, DBT- Institute of Life Sciences, Bhubaneshwar.

Non-Government Societies

- Jury Member for Sun Pharma Science Foundation's (formerly, Ranbaxy Science Foundation) Science Scholar Awards.
- Editorial board member of *Swiss Med Weekly, PLOS ONE, Frontiers Oncology* and *BMC Genomics*
- Faculty Member in Medical Genetics- *F1000 Prime*
- Jt Secretary, Molecular Pathologist Association of India
- Member, Society of Biological Chemists
- Associate Member, American Association of Cancer Research

RESEARCH GRANTS

2011-2012	Profiling the incidence of novel alteration discovered in human lung cancer	Seed-In-Air grant, Tata Memorial Center
2012-2015	Epidemiological study to evaluate the prevalence of epidermal growth factor receptor(EGFR mutation status in non-small cell lung cancer(NSCLC) in india.	Roche sponsored
2012-2015	Profiling the incidence of novel alteration discovered in human lung cancer	Terry Fox Foundation
2013-2017	Whole genome sequencing for identification of oncogenic mutations in cervical adenocarcinoma.	Terry Fox Foundation
2012-2017	Progestonomics of human breast cancer: a translational approach	Tata Memorial Center
2012-2017	Genome-wide RNAi screen with human pooled tyrosine kinase shRNA libraries in head and neck squamous cell carcinoma (HNSCC) cell lines	DBT- RNAi taskforce
2012-2018	Defining the cancer genome of head and neck squamous cell carcinoma (HNSCC) with snp arrays and next generation sequencing technology"	Wellcome Trust/ DBT India Alliance
2018-2021	Understanding the mechanistics of resistance to tyrosine kinase inhibitors in non-small cell lung cancer patients.	SERB, Dept of Science and Technology
2017-2022	Multi-Omics analysis to decipher mechanisms of hormone resistance and development of novel assays and therapeutic targets in endocrine receptor positive breast cancer	Dept of Biotechnology (DBT)/ VNCI
2020-2023	Deep learning approach for predicting nodal metastasis in tongue cancer using integrative genotype and radiological and pathological phenotype	DBT (approved, sanction awaited)
2023-2026	Characterizing the Mechanistic Insights and Clinical Relevance of Fusobacterium in Tongue Cancer	SERB, Dept of Science and Technology

PUBLICATIONS (*h-index: 36; i-10 index: 54; citations: 9611)*

2023

85: Dharavath B, Butle A, Pal A, Desai S, Thorat R, Upadhyay P, Nair S, **Dutt A**. *UBEC3-LRP5* Fusion is a Novel Oncogenic Driver in Head and Neck Cancer with Therapeutic Implications. ***npj Precision Oncol*** *(accepted).* **IF 10.1**

84: Chougule A, Chandrani P, Noronha V, Pange P, Kale S, Nikam A, Nambiar K, Marchande D, Durve A, Gupta V, Jagtap V, Tiwrekar P, Menon N, Joshi A, Kaushal R, Pai T, Patil VM, **Dutt A**, Banavali SD, Prabhash K. Real world evidence of EGFR targeted therapy in non-small cell lung cancer– a brief report of decade long single centre experience. *JTO Clinical and Research Reports (accepted).*

83: Chaubal R, Gardi NL, Joshi S, Pantvaidya G, Kadam R, Vanmali V, Hawaldar R, Talker E, Chitra J, Gera P, Bhatia D, Kalkar P, Gurav M, Shetty O, Desai S, Krishnan NM, Nair N, Parmar V, **Dutt A**, Panda B, Gupta S, Badwe RA. Surgical resection of tumors in cancer patients deregulates Hallmarks of Cancer in resected tissue and surrounding microenvironment. ***Mol Cancer Res*** *(under re-review).* **IF 5.2**

82: Desai S, Ahmad S, Bawaskar B, Rashmi S, Mishra R, Lakhwani D, **Dutt A**. Singleton Mutations in Large Scale Cancer Genome Studies: Uncovering the Tail of Cancer Genome. ***Briefings in Bioinformatics*** *(Accepted).* **IF 13.9**

81: Trivedi V, Noronha V,..Prabhash K, **Dutt A**. Association of *Cutibacterium* acne with human thyroid cancer. ***Frontiers in Endocrinology*** *(In Press).* **IF 6.1**

80: Gaur T, Poddutoori R, Khare L, Bagal B, Rashmi S, Patkar N, Tembhare P, Subramanian PG, Shetty D, **Dutt A**, *et al*. Novel Covalent CDK7 Inhibitor Potently Induces Apoptosis in Acute Myeloid Leukemia and Synergizes with Venetoclax. ***Journal of Experimental & Clinical Cancer Research.*** 2023 Jul 29;42(1):186. **IF 11.3**

79: Chakravorty G, Ahmad S, Godbole MS, Gupta S, Badwe RA, **Dutt A**. Deciphering the mechanisms of action progesterone in breast cancer. ***Oncotarget.***2023 Jul 1;14:660-667. **IF 5.1**

78: Rekhi B, Dave V, Butle A, **Dutt A**. Utility of immunohistochemical expression of H3.3K36M and DOG1 in the diagnosis of chondroblastomas: An experience from a tertiary cancer referral center. ***Ann Diagn Pathol.*** 2023 Jun 21;66:152174

77: Butti R, Kapse P, Bhadauriya G, Ahmad S, Chaubal R, Parab P, Kadam R, Mahapatra SS, Shet T, **Dutt A**, Gupta S, Kundu GC. Development and characterization of patient-derived orthotopic xenograft of therapy-resistant breast cancer. ***Oncol Rep.*** 2023 May;49(5). pii: 99. **IF 3.9**

76: Dharavath B, Butle A, Pal A, Desai S, Upadhyay P, Rane A, Khandelwal R, Manavalan S, Thorat R, Sonawane K, Vaish R, Gera P, Bal M, D'Cruz AK, Nair S, **Dutt A.** miR-944/MMP10/AXL- axis Predict Lymph Node Metastasis in Early Stage Tongue Cancer. ***Commun Biol.*** 2023 Jan 17;6(1):57. [The Indian Express][Nature Cancer Community] **IF 6.6**

2022

75: Yadav N, Sunder R, Desai S, Dharavath B, Chandrani P, Godbole M, **Dutt A.** Progesterone modulates the DSCAM-AS1/miR-130a/ESR1 axis to suppress cell invasion and migration in breast cancer. ***Breast Cancer Res.*** 2022 Dec 28;24(1):97 [The Hindu] **IF 8.4**

74: Noronha V, Chougule A, Chandrani P, Kaushal RK, Patil VM, Menon N, Kapoor A, Chopade S, Singh A, Shetty O, **Dutt A**, Banavali S, Prabhash K. Lung cancer with dual *EGFR* and *ALK* driver alterations at baseline: a retrospective observational cohort study. ***Acta Oncol***. 2022 Aug 16:1-5. **IF 4.3**

73: Rekhi B, Dodd L, Dharavath B, **Dutt A**. Cytomorphology of spindle cell/sclerosing rhabdomyosarcoma, including MYOD1 (LI22R) mutation result**.** ***Diagn Cytopatho.*** *2022*

72: Behel V, Noronha V, Choughule A, Shetty O, Chandrani P, Kapoor A, Bondili SK, Bajpai J, Kumar R, Pai T, Bal M, Gurav M, Bapat P, Mittal N, Menon S, Patil V, Menon N, **Dutt A**, Prabhash K. Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer. ***JCO Glob Oncol***. *2022 Jul;8* **IF 4.5**

71: Joshi A, Butle A, Hait S, Mishra R, Trivedi V, Thorat R, Choughule A, Noronha V, Prabhash K, **Dutt A.** Osimertinib for Lung Cancer Cells Harboring Low-Frequency *EGFR T790M* Mutation. ***Transl Oncol*** *2022.* [The Indian Express] **IF 5.0**

70: Desai S, Mishra R, Ahmad S, Hait S, Joshi A, **Dutt A.** TMC-SNPdb 2.0: an ethnic specific database of Indian germline variants. ***Database (Oxford)*** 2022. [India Science Wire-Vigran Prasar] **IF 5.8**

69: Desai S, Dharavath B, Manavalan S, Rane A, Redhu AK, Sunder R, Butle A, Joshi A, Togar T, Apte S, Bala P, Chandrani P, Bashyam MD, Banerjee A, Prabhash K, Nair S, **Dutt A**. *Fusobacterium nucleatum* is associated with inflammation and poor survival in early-stage HPV-negative tongue cancer. ***NAR Cancer*** 2022 [The Hindu] **IF 5.1**

2021

68: Butle A, Joshi A, Noronha V, Prabhash K, **Dutt A**. Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs. ***Transl Oncol***. 202 May 13;14(8):101111. **IF 4.2** [Research Matters]

67: Desai S, Rane A, Joshi, A, **Dutt A.** IPD 2.0: To derive insights from an evolving *SARS-CoV-2* genome. ***BMC Bioinformatics***. 2021 May 13;22(1):247 **IF 3.2** [nature India] [India Bioscience][The Hindu][Indian Express][Business Standard][Fortune][The Print][The Federal]

66: Joshi A, Mishra R, Desai S, Chandrani P, Kore H, Sunder R, Hait S, Iyer P, Trivedi V, Choughule A, Noronha V, Joshi A, Patil V, Menon N, Kumar R, Prabhash K, **Dutt A.** Molecular Characterization of Lung Squamous Cell Carcinoma Patients of Indian Descent Reveal Therapeutically Relevant Alterations. ***Oncotarget***. **IF 5.1** [News Med Lif Sci][Mirage News][Bioengineer.org][ScienMag] [EurAlert]

65: Desai S, Rashmi S, Rane A, Dharavath, B, Sawant A, **Dutt A.** An integrated approach to determine the abundance, mutation rate and phylogeny of the SARS-CoV-2 genome. ***Briefings in Bioinformatics***, 2020 (*In Press*). **IF: 11.6, Citation: 17** [nature India][IndiaBioscience][The Hindu][Indian Express][Business Standard][Fortune][The Print][The Federal]

2020

64: Salunkhe S, Mishra SV, Ghorai A, Hole A, Chandrani P, **Dutt A**, Chilakapati M, Dutt S. Metabolic rewiring in drug resistant cells exhibit higher OXPHOS and fatty acids as preferred major source to cellular energetics. ***Biochim Biophys Acta Bioenerg***. 2020 Aug 25;1861(12):148300. doi: 10.1016/j.bbabio.2020. **IF: 4.5, Citation: 25**

63: Dharavath B, Yadav N, Desai S, Sunder R, Mishra R, Ketkar M, Bhanshe P, Gupta A, Redhu AK, Patkar N, Dutt S, Gupta S, **Dutt A**. A one-step, one-tube real-time RT-PCR based assay with an automated analysis for detection of SARS-CoV-2. ***Heliyo***n. 2020 Jul 7;6(7):e04405. **Citation: 30** [Sci Soup] [The Hawk] [Biotech Times] [India Today] [Research Stash]

62: Desai S, Vatsa Mishra S, Joshi A, Sarkar D, Hole A, Mishra R, Dutt S, Chilakapati MK, Gupta S, **Dutt A**. Raman Spectroscopy Based Detection of RNA viruses in Saliva:a preliminary report. ***J Biophotonics***. 2020 Jul. **IF: 3.8, Citation: 50** [The Hindu][India Today][JMI] [Clinical Omics] [WITech] [Dhyeya IAS]

61: Kaur E, Nair J, Ghorai A, Mishra SV, Achareker A, Ketkar M, Sarkar D, Salunkhe S, Rajendra J, Gardi N, Desai S, Iyer P, Thorat R, **Dutt A**, Moiyadi A, Dutt S.Inhibition of SETMAR-H3K36me2-NHEJ repair axis in residual disease cells prevent glioblastoma recurrence. ***Neuro Oncol***. 2020 May 27. **IF: 12.3**

60: Togar T, Desai S, Mishra R, Terwadkar P, Ramteke M, Ranjan M, Kawle D, Sahoo B, Pal A, Upadhyay P, **Dutt A**. Identifying cancer driver genes from functional genomics screens. ***Swiss Med Wkly***. 2020 Feb 21;150:w20195.

2019

59: Sikder S, Kumari S, Kumar M, Sen S, Singhal N, Chellappan S, Godbole M, Chandrani P, **Dutt A**, Gopinath K, Kundu T. Multifunctional human chromatin protein PC4 is downregulated in Breast Cancer to promote disease progression: Implications of miR-29a. ***Oncotarget*** (2019) **IF: 5.0**

58: Arora R, Rekhi B, Chandrani P, Krishna S, **Dutt A**. Merkel cell polyomavirus is implicated in a subset of Merkel cell carcinomas, in the Indian subcontinent. ***Microbial Pathogenesis***. 2019 **IF: 3.7** [Med Xpress]

57: Noronha V, Patil VM, Joshi A, …, **Dutt A**, Banavali SD, Prabhash K. Gefitinib vs gefitinib with pemetrexed-carboplatin chemotherapy in EGFR mutated lung cancer (gef vs gef+C). ***Journal of Clinical Oncology***. (2019) **IF: 44.54; Citation: 306**

56: Singh S, Kumar M, Kumar S, Sen S, Upadhyay P, Bhattacharjee P, Naveen M, Tomar SV, Roy S, **Dutt A**, Kundu TK. The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis**.** ***J Biol Chem*** (2019) **IF: 5.2**

55: Pahuja KB, Nguyen TT, …**Dutt A** et al. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. ***Cancer Cell***. 2018 Nov 12;34(5):792-806 **IF: 31.7; Citation: 104**

54: Iyer P[,], Shrikhande SV, Ranjan M, Joshi A[,], Gardi N, Prasad R, Dharavath B[,], Thorat R, Salunkhe S[,], Sahoo B, Chandrani P, Kore H, Mohanty B, Chaudhari V, Choughule A, Kawle D, Chaudhari P, Ingle A, Banavali S, Gera P, Ramadwar MR, Prabhash K, Barreto SG, Dutt S, **Dutt A**. *ERBB2* and *KRAS* Alterations Mediate Response to EGFR Inhibitors in Early Stage Gallbladder Cancer. ***International Journal of Cancer***. 2019 **IF: 7.4; Citation: 38**[natureINDIA][wellcomedbt][TheHindu][India Bioscience]

2018

53: Godbole M, Togar T, Patel K, Dharavath B, Yadav N, Janjuha S, Gardi N, Tiwary K, Terwadkar P, Desai S, Prasad R, Dhamne H, Karve K, Salunkhe S, Kawle D, Chandrani P, Dutt S, Gupta S, Badwe RA, **Dutt A***. Up-regulation of the kinase gene *SGK1* by progesterone activates the AP-1—NDRG1 axis in both PR-positive and -negative breast cancer cell. ***J Bio Chem***. 2018. **IF: 5.2; Citation: 26**

52: Salunkhe S, Chandran N, Chandrani P, **Dutt A**, Dutt S. CytoPred: 7 gene pair metrics for AML cytogenetic risk prediction. ***Briefings in Bioinformatics***. 2018; (*In press*) **IF: 11.6; Citations:5**

51: Balaji SA, Shanmugam A, Chougule A, Sridharan S, Prabhash K, Arya A, Chaubey A, Hariharan A, Kolekar P, Sen M, Ravichandran A, Katragadda S, Sankaran S, Bhargava S, Kulkarni P, Rao S, Sunkavalli C, Banavali S, Joshi A, Noronha V, **Dutt A**, Bahadur U, Hariharan R, Veeramachaneni V, Gupta V. Analysis of solid tumor mutation profiles in liquid biopsy. ***Cancer Med***. 2018 Sep 27. doi: 10.1002/cam4.1791. **IF: 4.5; Citation: 18**

50: Barreto SG, **Dutt A**, Sirohi B, Shrikhande SV. Gallbladder cancer: a journey of a thousand steps. ***Future Oncol***. 2018 Jun;14(13):1299-1306. doi: 10.2217/fon-2017-0576. **IF: 3.4**

49: Veldore VH, Choughule A, Routhu T, Mandloi N, Noronha V, Joshi A, **Dutt A**, Gupta R, Vedam R, Prabhash K. Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer. ***Lung Cancer (Auckl)***. 2018 Jan 3;9:1-11 **IF: 5.7; Citation: 58**

48: Chatterjee S, Chaubal R, Maitra A, Gardi N, **Dutt A**, Gupta S, Badwe RA, Majumder PP, Pandey P. Pre-operative progesterone benefits operable breast cancer patients by modulating surgical stress.***Breast cancer research and treatment***. 2018;170(2):431-438 **IF:4.9;Citation: 10**

47: Rajendra J, Datta KK, Ud Din Farooqee SB, Thorat R, Kumar K, Gardi N, Kaur E, Nair J, Salunkhe S, Patkar K, Desai S, Goda JS, Moiyadi A, **Dutt A**, Venkatraman P, Gowda H, Dutt S. Enhanced proteasomal activity is essential for long term survival and recurrence of innately resistant residual glioblastoma cells ***Oncotarget***. 2018; 9(45):27667-27681. **IF: 5.0; Citation: 12**

2017

46: Godbole M, Chandrani P, Gardi N, Dhamne H, Patel K, Yadav N, Gupta S, Badwe R, **Dutt A***. *miR-129-2* mediates down-regulation of progesterone receptor in response to progesterone in breast cancer cells. ***Cancer Biology & Therapy***. 2017 **IF: 4.7; Citation: 21** [The Hindu]

45: Godbole M, Sharma K, Badwe R, Gupta S, **Dutt A***. Progesterone suppresses the invasion and migration of breast cancer cells irrespective of their progesterone receptor status. ***Cellular Oncology*** 2017; 40(4):411-417. **IF: 6.7; Citation: 21** [wellcomedbt] [The Hindu]

44: Upadhyay P, Gardi N, Desai S, Chandrani P, Joshi A, Dharavath B, Arora P, Bal M, Nair S, **Dutt A***. Genomic characterization of tobacco/nut chewing HPV-negative early stage tongue tumors identify MMP10 as a candidate to predict metastases. ***Oral Oncology*** 73 (2017) 56–64 **IF: 5.3; Citation: 38**
[natureINDIA] [IndiaBioscience] [wellcomedbt] [The Hindu][Atlas of Science][The Hawk]

43: Noronha V, Chougule A, Patil VM, Joshi A, Kumar V, Philip DSJ, Banavasi S, **Dutt A**, Prabhash K. Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment. ***OncoTargets and Therapy***. 2017; 10:2903-2908 **IF: 4.1; Citation: 39**

42: Bhat S, Gardi N, Hake S, Kotian N, Sawant S, Kannan S, Parmar V, Desai S, **Dutt A**, Joshi NN. Impact of intra-tumoral IL17A and IL32 gene expression on T-cell responses and lymph node status in breast cancer patients. ***Journal of Cancer Research and Clinical Oncology***. 2017; 143(9):1745-1756. **IF: 4.55; CI: 16**

41: Mittra I, Samant U, Sharma S, Raghuram GV, Saha T, Tidke P, Pancholi N, Gupta D, Prasannan P, Gaikwad A, Gardi N, Chaubal R, Upadhyay P, Pal K, Rane B, Shaikh A, Salunkhe S, Dutt S, Mishra PK, Khare NK, Nair NK, **Dutt A** (2017). Cell-free chromatin from dying cancer cells integrate into genomes of bystander healthy cells to induce DNA damage and inflammation. ***Cell Death Discovery*** **3**, 17015; 2017 **IF: 5.2; Citation: 93** [IndiaBioscience]

2016

40: Chandrani P, Prabhash K, Choughule A, Prasad R, Sethunath V, Ranjan M, Iyer P, Aich J, Dhamne H, Iyer DN, Upadhyay P, Mohanty B, Chandna P, Kumar R, Joshi A, Noronha V, Patil V, Ramaswamy A, Karpe A, Thorat R, Chaudhari P, Ingle A, **Dutt A***. Drug-sensitive *FGFR3* mutations in lung adenocarcinoma. ***Annals of oncology: official journal of the European Society for Medical Oncology***. 2016 **IF: 33; Citation: 38** [natureINDIA] [India Bioscience] [wellcomedbt] [Indian Express]

39 Rekhi R, Upadhyay P, Ramteke M, and **Dutt A***. *MYOD1* (L122R) Mutations Are Associated with Spindle cell / Sclerosing Rhabdomyosarcomas with Aggressive Clinical Outcomes. ***Mod Pathology*** 2016. **IF: 7.8; Citation: 91**

38. Barreto SG and **Dutt A*.** To improve outcomes of gallbladder cancer we need to better understand it! ***Hepatobiliary Surg Nutr*** 2016;5(4):379-381. doi: 10.21037/hbsn.2016.05.06

37. Kaur E, Sahu A, Hole AR, Rajendra J, Chaubal R, Gardi N, **Dutt A.**, Moiyadi A, Krishna CM, Dutt S. Unique spectral markers discern recurrent Glioblastoma cells from heterogeneous parent population. ***Sci Rep.*** 2016 May 25;6:26538 **IF: 4.4; Citation: 16**

36. Upadhyay P, Gardi N, Desai S, Sahoo B, Singh A, Togar T, Iyer P, Prasad R, Chandrani P, Gupta S, **Dutt A*.** TMC-SNPdb: an Indian germline variant dataset derived from whole exome sequence. ***Database***, 2016, 1–8. **IF: 4.0, Citation: 12** [TMC-SNPdb] [Wellcomedbt]

35. Upadhyay P, Nair S, Kaur E, Aich J, Dani P, Sethunath V, Gardi N, Chandrani P, Godbole M, Sonawane K, Prasad R, Kannan S, Agarwal A, Kane S, Gupta S, Dutt S, **Dutt A*.** Notch pathway activation is essential for maintenance of stem-like cells in early tongue cancer. ***Oncotarget*** 2016 **IF:5.0; Citation: 40** [Wellcomedbt]

34: Iyer P, Barreto SG, Sahoo B, Chandrani P, Ramadwar MR, Shrikhande SV, **Dutt A*** Non-typhoidal Salmonella DNA traces in gallbladder cancer. ***Infect Agent Cancer***. 2016 Mar 3;11:12. **IF: 3; Citation: 51** [IndiaBioscience] [Wellcomedbt]

2015

33. Chandrani P, Upadhyay P, Iyer P, Tanna M, Shetty M, Raghuram GV, Oak N, Singh A, Chaubal R, Ramteke M, Gupta S, **Dutt A***. Integrated Genomics Approach to Identify Driver Alteration. ***BMC Genomics.*** 2015 Nov 14;16(1):936. doi: 10.1186/s12864-015-2138-4. **IF: 4.0; Citation: 9**

32. Ramteke MP, Patel KJ, Godbole M; Vyas M, Karve K, Choughule A, Prabhash K, **Dutt A*.** CRE: a cost effective and rapid approach for PCR-mediated concate of *KRAS* and *EGFR* exons ***f1000Research*** 06/2015; 4(160).

31. Barreto SG, Barreto M, Chaubal R, **Dutt A** The fight against cancer: Is it worthwhile? **Indian J Med Paediatr Oncol**.. 2015 Apr-Jun;36(2):85-6. doi:10.4103/0971-5851.158833.

30: Chandrani P, Kulkarni V, Iyer P,.Randeep Singh, **Dutt A*.** NGS Based Approach to Determine the Presence of HPV and Their Sites of Integration in Human Cancer Genome. ***Br J of Cancer***. 2015 May 14. **IF: 7.6; Citation: 66** [HPVDetector] [Wellcomedbt]

29: Mittra I, Khare NK…. **Dutt A**. Circulating nucleic acids damage DNA of healthy cells by integrating into their genome and induce oncogenic transformation. ***J Biosci***.2015 Mar;40(1):91-111.**IF: 1.8;Citation: 93**

2014

28: Choughule A, Sharma R, Trivedi V, .. Aich J, Prabhash K, **Dutt A***. Coexistence of *KRAS* mutation with mutant but not wild type EGFR predict response to tyrosine-kinase inhibitors in human lung cancer. ***British J of Cancer,*** 12 August 2014. **IF: 7.6; Citation: 40**

27: Upadhyay P, Dwivedi R, **Dutt A*** Application of NGS in Cancer Research. ***Current Sc***,2014; 107 (5), 795

26: Barreto SG, **Dutt A***, Adarsh Chaudhary. A Genetic Model for Gallbladder Carcinogenesis and its Dissemination. ***Annals of Oncology*** 2014 **IF: 33; Citation: 71** [A commentary on this article]

2013

25: Chougule A, Prabhash K, Noronha V, Joshi A, Thavamani A, Chandrani P, Upadhyay P, Utture S, Desai S, Jambhekar N, **Dutt A***. Frequency of *EGFR* Mutations in 907 lung adenocarcioma Patients of Indian Ethnicity. ***PLoS One.*** 2013 Oct 4;8(10):e76164. **IF 3.2; Citation: 107**

24: Chougule A, Prabhash K, Noronha V, Joshi A, Thavamani A, Chandrani P, Upadhyay P, Utture S, Desai S, Jambhekar

N, **Dutt A***. *EGFR* Mutation Subtypes and Geographical Distribution Among Indian NSCLC Patients. ***Indian J Cancer***. 2013 Apr-Jun;50(2):107. **IF: 1.2; Citation: 37**

23: Noronha V, Prabhash K, … **Dutt A***, Mulherkar R. EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy. ***PLoS One***. 2013 Apr 19;8(4):e61561 **IF: 3.2; Citation: 76**

22: Kumar R, Horvath A… **Dutt A** et al. The Global Cancer Genomics Consortium's Second Annual Symposiu: Genomics Medicine in Cancer**.** ***Genes & Cancer*** 2013.

2012

21: Eswaran J, Gupta S, **Dutt A**, et al. The Global Cancer Genomics Consortium: Interfacing Genomics and Cancer Medicine. ***Cancer Res.*** 2012 May 24.

2011

20: Cho J, ..**Dutt A**, et al. Glioblastoma-derived EGFR carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.***Cancer Res***. 2011 **IF 3.2; Citation: 76**

19: Dutt A* et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. ***PLoS One*****.** 2011;6(6):e20351. **IF 3.2; Citation: 438**

18: Hammerman P, Sos ML, Ramos AH, Xu C, **Dutt A** et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. ***Cancer Discovery*** 2011. **IF 3.2; Citation: 568**

2010 and earlier (from Post Doc and Ph.D.)

17: Zhou W, Hur W, McDermott U, **Dutt A** et al. A Structure-guided Approach to Creating Covalent FGFR1 Inhibitors. ***Chem Biol.*** 2010 Mar 26;17(3):285-95 **IF 5.9; Citation: 199**

16: Bass AJ, Watanabe H… **Dutt A et al.** SOX2 Is an Amplified Oncogene in Lung and Esophageal Squamous Cell Carcinoma. ***Nat Genet.*** 2009 Nov;41(11):1238-42. **IF 27.6; Citation: 1022**

15: Ramos AH[$], **Dutt A**[$] et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. ***Cancer Biol Ther***. 2009 Nov;8(21):2042-50. [$] co-first authors. **IF 3.7; Citation: 102** [News and views]

14: Dutt A, Salvesen H, Greulich H, Sellers WR, Beroukhim R, Meyerson M. Somatic mutations are present in all members of the AKT family in endometrial carcinoma. ***Br J of Cancer***; 2009;101(7):1218-9 **IF 5.8; Citation: 38**

13: Salvesen HG, Cartel L, Mannelqvist M, **Dutt A** et al., Gene expression profiles identify an aggressive subtype of endometrial carcinoma associated with amplification and of PIK3CA. ***PNAS USA***. 2009 **IF 11.2; Citation: 344**

12: Ding L, Gedz Gad … **Dutt** A et al. Somatic mutations affect key pathways in lung adeno carcino ***Nature***. 2008 Oct 23;455(7216):1069-75. **IF 49.9; Citation: 2986**

11: **Dutt A**, et al.. Drug-sensitive *FGFR2* mutations in endometrial carcinoma. ***Proc Natl Acad Sci U S A***. 2008 Jun 24;105(25):8713-7. **IF 11.2; Citation: 400**

10: Thomas RK… **Dutt A** et al. High-throughput oncogene mutation profiling in human cancer. ***Nat Genet***. 2007 Mar;39(3):347-51. **IF 27.6; Citation: 1130**

9: **Dutt A**, Beroukhim R. Single nucleotide polymorphism array analysis of cancer. s***Curr Opin Oncol***. 2007 Jan;19(1):43-9. Review. **IF 3.4; Citation: 141**

8: **Dutt A**, Wong KK. Mouse models of lung cancer. ***Clin Cancer Res***. 2006;12(14):4396-4402s. **IF 12.5; Citation: 64**

7: Murtaza I… **Dutt A** et al. A study on p53 gene alterations in esophageal squamous cell carcinoma and their correlation to common dietary risk factors among population of the Kashmir valley. ***World J Gastroenterol*** 2006 Jul 7;12(25):4033-7. **IF 3.7; Citation: 73**

6: Murtaza I.. **Dutt A**. A preliminary investigation demonstrating the effect of quercetin on the expression of genes related to cell-cycle arrest, apoptosis and xenobiotic metabolism in human CO115 colon-adenocarcinoma cells using DNA microarray. **Biotechnol Appl Biochem**. 2006 Jul;45(Pt 1):29-36. **IF 1.6; Citation: 58**

5: Murtaza I, **Dutt A**, Mushtaq D, Ali A. Molecular cloning and genetic analysis of functional merB gene from indian isolates of Escherichia coli. ***Curr Microbiol***. *2005* Nov;51(5):297-302. **IF 1.7; Citation: 12**

4: **Dutt A**, Canevascini S, Froehli-Hoier E, Hajnal A. EGF signal propagation during C. elegans vulval development mediated by ROM-1 rhomboid. ***PLoS Biol***. 2004 Nov;2(11):e334. **IF 7.0; Citation: 80**

3: Murtaza I, **Dutt A**, Ali A. Relationship between the persistence of mer operon sequences in Escherichia coli and their resistance to mercury. ***Curr Microbiol***. 2002 Mar;44(3):178-83. **IF 1.7; Citation: 24**

2: Murtaza I, **Dutt A** and Ali Arif 2002 Biomolecular engineering of organomercurial lyase in *Escherichia coli*. ***Indian J. Biotech***. 2002;1:117-120. **(ISSN: 0972-5849)**

1: Murtaza I, **Dutt A** and Ali Arif. 2001 Inducible mercury operons in Broad Spectrum *Escherichia coli* ***Ind. J. Microbiol.*** *2001; 41:169-172****, (ISSN: 0046-899)***

PUBLICATIONS (Book Chapters)

1: Asim Joshi, Bhasker Dharavath, Aniket Chowdhary, Rudransh Singh, Sanket Desai, and Amit Dutt. Cahpter in Book entitle, "Genetic alterations and microbial dysbiosis underlie lymph node metastasis in tongue cancer", in Handbook of Oncobiology: From Basic to Clinical Sciences, edited by- Rakesh Kumar and RC Sobti, 2023.

2: Pratik Chandrani and **Amit Dutt** Domain specific Targeting of Cancer. Chapter XII in Book entitled, "Nuclear Signaling Pathways and Targetting Transcription in Cancer", Springer Science & Business Media, 2013; 299-310 ISBN: 978-1-4614-8039-6.

3: Next Generation Sequencing and Cancer Biology, by **Amit Dutt**-- an invited article in "Cutting Edge", May 2012, A Spinco Biotech Publication.

ACADEMIC ACTIVITIES

h index: 36; *Citations*: 9611; *Research Interest Score*: 3,969; https://orcid.org/0000-0002-1119-4774

Number of Ph.D students graduated: **Nine**
Number of Ph.D students currently pursuing Ph.D: **Six**
Number of Postdocs trained: **Five**
Number of Postdocs currently pursuing: **Three** (*One core ACTREC PDF; one NPDF; one DBT RA fellow*)
Number of Thesis examiners: **Fifteen**
Number of Doctoral committee members served/ serving: **Fourteen**

INVITED INTERNATIONAL PRESENTATIONS

2023

- Invited speaker and faculty to the Excellence in Oncology Care 2023 at the 8th edition of the UAE Cancer Congress from 6th- 8th October 2023 held at **Dubai, United Arab Emirates**.

2022

- Invited speaker and faculty to the Lung Cancer Session at the 8th edition of the UAE Cancer Congress from 21st- 22nd October 2022 held at the Inter Continental Hotel Festival City **Dubai, United Arab Emirates**.

2019

- Invited guest lecture (as a part of Special Distinguished Lecture Series) on 3 May 2019, at the GSU organized by the Molecular Basis of Disease Area of Focus (MBDAF) at **Georgia State University, Atlanta, USA**.
- Invited speaker at Global Academic Programs Annual Conference- **GAP2019, Houston,** 30 Apr -2 May 2019.
- Invited Speaker from Apr 28-29 at the Dept of Genetics, **MD Anderson Cancer Centre, Houston, USA**

2018

- Invited Speaker at the Annual GAP Conference 2018 "Global efforts fighting cancer", **Karolinska Institutet and Karolinska University Hospital, Stockholm, Swede**n, from May 15-17, 2018.
- Invited Speaker to a Special Seminar by the Institute of **Molecular Life Sciences, University of Zurich, Switzerland** on May 11, 2018

2017

- Invited speaker to the International conference (ICGCK 2017) to be held in **Seoul National University, Seoul** on Oct 26-27, 2017
- Invited Speaker to the Researcher Meeting: Genetics and Physiology in Health and Disease by the **Wellcome Trust, held in June 2017, Cambridge, UK**

2016

- Invited speaker and faculty to the Lung Cancer Session at the 8th edition of the UAE Cancer Congress from 21st- 22nd October 2016 held at the Inter Continental Hotel Festival City **Dubai, United Arab Emirates**.
- Invitation to present at the inaugural Cancer-Disease Ontology workshop organized from Apr 10- 14th in **Geneva, Switzerland**
- Invited speaker to the Helga Salvesen Memorial Symposium at the **Broad Institute of Harvard and MIT on 24th October 2016, Boston**

2015

- Invited Speaker at the Global Cancer Genomic Conference, Nov 2015 at **Jiujiang University, Nanchang, China**
- Invited Speaker at the **Beijing Genomics Institute, Nov 2015 at Shenzhen, China**.

2014

- Invited Speaker to the 3rd **Global Cancer Genomics Consortium annual meeting, Kyoto, Japan** organized from Nov 18-20, 2014

2013

- Invited guest speaker/faculty at the **Global Cancer Genomics Consortium – Instituto de Medicina Molecular (GCGC – IMM), Symposium, Lisbon, Portugal** from September 19 – 20, 2013

2012

- Invited Faculty at **Illumina Asia Pacific Scientific Summit, Gold Coast Queensland, Australia**, Apr 2012

2011

- Invited particpant at the US-India BioPharma Summit 2012, organized by **USA-India Chamber of Commerce, Boston, USA**, May 2011

INVITED NATIONAL PRESENTATIONS

~200 odd invited presentations between 2011 and 2023

PROFESSIONAL CO-CURRICULAR ACTIVITIES

17. Co-Organizer of the XIX Annual Conference on Evidence Based Management of Cancers in India- Tata Memorial Centre 2021, "Technology and Cancer Care - Promise and Reality of the Brave New World"

16. Organizer of the 2nd UK-India Cancer Bioinformatics Workshop on 'Next-Generation Sequencing Data Analysis' – jointly funded by Tata Memorial Centre and Kings College London—from Oct 31-Nov 2nd 2019.

15. On the expert panel of Dept of Science and Technology, Govt of Haryana for Haryana Vigyan / Yuva Vigram Ratan Awards for 2017 and 2018

14. Regular special invitees to several SERB DST "CRG-BHS-PACs" meetings

13. Innovative Young Biotechnologist Award (IYBA) DBT Expert Screening Committee Member for 2018, 2019

12. Organizer of the Cancer Informatics pre-Conference Workshop at the 38th Annual IACR Conference, Chandigarh

11. Organizer of the 7th Molecular Pathologist Association of India (MPAI) meeting 2019 at ACTREC, Tata Memorial Centre, Mumbai (http://mpai.co.in/conference.html), along with a pre conference workshop on NGS Data Analysis

10. Organizer of the UK-India Cancer Bioinformatics Workshop on 'Next-Generation Sequencing Data Analysis' – jointly funded by Tata Memorial Centre and Kings College London—from Oct 28-31 2018.

9. Organizer of DBT Sponsored Cancer Informatics Workshop on Next Gen Data Analyis from Jan 28-30, 2013

8. Co-organized the TMC 75th Platinum jubilee conference with theme, "A conference of new ideas in cancer - challenging dogmas" from Feb 24-26, 2016 in Mumbai.

7. Advisory Board of DiseaseBiology.info; of Aegle Sciences; and, inDNA Research Labs Pvt Ltd.

6. Organized the DBT Sponsored Cancer Informatics Workshop on Next Gen Data Analyis from Jan 28-30, 2013 (http://www.actrec.gov.in/pi-webpages/AmitDutt/cwi_workshop.html)

5. Organized the Second Global Cancer Genome Consortium (GCGC) TMC Symposium at ACTREC, Nov 2012—an initiative by three leading academic institutions; George Washington University, USA, Oxford University, UK and Tata Memorial Centre India (http://www.gcgc.in)

4. Organized the first Global Cancer Genome Consortium (GCGC) TMC Symposium at ACTREC, Nov 2011—an initiative by hree leading academic institutions; George Washington University, USA, Oxford University, UK and Tata Memorial Centre India (http://www.gcgc.in)

3. Organized (along with a group fellow scientsits) The Young Investigator Meeting Boston 2010 at The Broad Institute of Harvard and MIT-- http://www. yimboston.org.

2. Active organizer and volunteer for the USA-India Biopharma Summit for the years 2008, 2009, 2010 and for 2011- http://www.usaindiachamber.org/current-events.shtml

1. Initiated and established (along with a group of fellow graduate students) Indian Student Association of Zurich- http://www.insaz.ethz.ch/

SELECTED NEWS MEDIA REPORTS

miR-944/MMP10/ AXL- axis Predict Metastasis in Tongue Cancer [Nature Cancer Community]
Breast cancer: more insights on how hormonal therapy works [The Hindu]
Researchers develop India-specific cancer genome toolkit [India Science Wire-Vigyan Parisar]
Tata Memorial develops novel biomarker for tongue cancer spread to spare 70% patients from neck surgery [The Indian Express]
Breast cancer: more insights on how hormonal therapy works [The Hindu]
Cancer vanishing drug trial exciting but far from a breakthrough [The Indian Express]
New study recommends next-generation sequencing for extending lung cancer treatment to more patients [The Indian Express]
Lung squamous patients harboring druggable mutations have lower median overall survival [News Medical]
75 under 50: Scientists Shaping Today's India [DST, Govt of India]
The role *Fusobacterium* plays in oral cancer patients in India [The Hindu]
TARGT Indiegene NGS panel [ANI News]
Study finds popping a weekly cancer pill instead of daily is enough to prevent regrowths [Research Matters]
Tool to ease SARS-CoV-2 genome mutation analysis [The Hindu]
A computational tool that can rapidly identify and analyse coronavirus mutations [IndiaBioscience]
Software that helps analyse coronavirus genome for mutations [Nature India]
Do declining Covid-19 numbers suggest pandemic is nearing its end in India? [Indian Express]
Indian scientists create new computational tool to track Covid-19 mutations worldwide [The Print]
Vaccine efficacy: What's holding India back from ramping up genome sequencing [The Federal]
A Blueprint To Develop A Rapid qRT-PCR kit To Detect SARS-CoV-2 [SciSoup]
Detecting RNA virus in saliva samples using Raman spectroscopy[The Hindu]
Potential therapy for drug-defying gallbladder cancer [Nature India]
How progesterone protects breast cancer patients unravelled[The Hindu]
Existing drug can be used for treating gallbladder cancer[The Hindu]
TMC overcomes resistance to hormonal therapy for breast cancer[The Hindu]
Biomarker tells of tongue cancer spread[The Hindu]
New genetic marker for oral cancer[Nature India]
Potential therapy for lung cancer[Nature India]
A new and free computational tool for HPV detection[India Alliance]
For lung cancer patients in India, key to treatment could be malfunctioning gene[Indian Express]
Novel genetic marker identified for lung adenocarcinoma[India Bioscience]
Non-typhoidal Salmonella in gallbladder cancer[India Bioscience]
Fighting cancer is team work at Tata Memorial [Times of India]
How genetic data of Indian lung cancer patients can now help them get better treatment [*Lignum Vitae*]
It is a moment of pride for Jamia Millia Islamia[Okhla Times]
[Wikipedia] [The Wire] [The Hindu]

1. **Genetic testing at an affordable pricing:** Our efforts led to the development of a diagnostic test to detect *EGFR* mutations for lung cancer patients, which **reduces its cost from ~$250 to ~$12 per test that is currently being offered at the Tata Memorial Hospita**l on routine basis (*Br J Cancer 2014; PLoS One 2013 Apr; PLoS One; 2013 Oct)*.
2. **VARS**: a joint initiative by ACTREC and **Vekaria Health Care LLP Pvt Ltd**. A real time RT PCR based COVID detection kit developed in my lab has successfully been transferred to industry through a formal institutional MOU, under a trade name "VARS". (*Heliyon*, 2021)
3. **ClinOme**, a Graphical User Interface (GUI) based automated tool, developed in my laboratory has recently moved from my laboratory settings to the Medical Oncology Department at the Tata Memorial Hospital. The ClinOme has been successfully transferred to industry through a formal institutional MOU to **4baseCare Genomics Pvt Ltd** —for commercial purpose. A collaboration agreement was finalized and purchased by the 4baseCare Genomics Pvt Ltd for joint development and ownership of the Intellectual Property rights with ACTREC,Tata Memorial Centre.
4. **Raman Spectroscopy Based Detection of RNA viruses:** Similar to the Israeli developed spectroscopy-based one minute breathe analyzer to detect coronavirus, we developed a proof of principle study using Raman Spectroscopy, published in *Journal of Biophotonics*. The technology was explored for transfer through an institutional process to **Quantificare Health Stations Pvt. Ltd**, a Hyderabad based company with an existing network of Internet of Things (IOT)-based Smart kiosks called Pulse Active Stations.
5. **HPVDetector**: We developed a novel freely distributable computational tool "HPVDetector' to detect all known HPV types along with their sites of integration in the host genome using next generation sequencing data set (*Br J Cancer 2015*). It has been downloaded and currently been used by above 350 laboratories across 39 countries, and multiple international companies has expressed written interest for permission to integrate the tool in their commercial pipeline.
6. We developed the **TMC-SNPdb-- first Indian SNP reference database** based on whole exome sequencing fills the void due to lack of Indian germline variant database (*Database 2016*). The TMC-SNPdb database has been downloaded and is being used at 200 different research labs across the 13 countries. More recently, this was updated with the release of TMC-SNPdb 2.0 (*Database* 2022)—a database of germline variants from 1800 individuals.
7. Recently, we developed an *in-silico* GUI-based automated pathogen analysis pipeline for seamless analysis of data from heterogenous NGS platforms. The Infectious Pathogen Detector (IPD) performs integrated variants analysis, along with systematic quantification of pathogen genomes (*Briefings in Bioinformatics* 2021, *BMC Bioinformatics* 2021*)*. The IPD is currently in used at more than 50 different research labs across the 11 countries.
8. **TARGT Indiegene NGS panel**: In collaboration with a precision oncology company 4baseCare, we developed and launched one-of-its-kind Indian population specific cancer gene panel from whole exome and whole transcriptome data from 1,500 cancer patients.

CoviScience@ACTREC (donation for charity) *an initiative for the underprivileged*

I led the CoviScience@ACTREC, a reach-out program launched by a group of scientists in May 2021 to fight the COVID-19 pandemic. The initiative aims to vaccinate and educate the underprivileged population in their neighborhood. The objectives include busting vaccine hesitancy, distributing sanitation kits, and disseminating accurate scientific information.The initiative targeted frontline workers such as garbage collectors, sweepers, vendors, security guards, and domestic help. Vaccinations are facilitated at a private clinic, and eligible beneficiaries are registered through various methods, including residential complex societies, marketplaces, and online platforms. Funds, **to a total of Rs 21 lakhs**, for purchasing vaccines were generated through crowdfunding from friends and family in India and abroad. We successfully **administered 6,557 vaccine doses** to underprivileged individuals, along with providing certificates and sanitation kits.

Creation of R G Manudhane Scholarship Fund at ACTREC for Ph.D. students

I established the **R G Manudhane Scholarship Fund (RGMS fund) by creating a corpus of Rs 60 Lakhs** through a single, generous philanthropic donation. The fund aims to provide support to Ph.D. students at ACTREC who are experiencing a shortage in their fellowship disbursement from national funding agencies. With the assistance of the RGMS fund, students at ACTREC can now receive a consistent salary, addressing the issue of interrupted monthly fellowships. This initiative has effectively alleviated a significant challenge faced by Ph.D. students throughout India, at ACTREC.